Advertisement
Advertisement
U.S. markets close in 1 hour 26 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Santhera Pharmaceuticals Holding AG (SPHDF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.41000.0000 (0.00%)
As of 03:28PM EDT. Market open.
Advertisement
Sign in to post a message.
  • L
    LuckyD
    Santhera Pharmaceuticals Holding AG, based in Pratteln, is a Swiss pharmaceutical company specializing in rare neuromuscular and pulmonary diseases. Founded in 2004, the company has been listed on the Swiss stock exchange SIX Swiss Exchange since 2006.

    https://www.santhera.com/

    Within the next 5 months the FDA will decide on the approval of Vamorolone which is a state of the art dissociative steroid for patients diagnosed with Duchenne muscular dystrophy (DMD).

    Vamorolone has a peak sales potential in the US and the EU combined of $500.000.000 per year.

    From an investors' perspective, it is basically a bet on the decision on the approval of the FDA.
    If Vamorolone gets the approval, you can expect 10x short to midterm and even more long term. If it doesn't get the approval, chances are high the company won't exist much longer.
    So all or nothing.

    The Dec. 2019 appointed CEO is a winner, check is vita. Since he took over, he delivered.
    https://ch.linkedin.com/in/darioeklund

    For me, it is so far the best investment opportunity of my life. Success chances are high.
    Check: https://www.valuationlab.com/research/

    The product will help sick children as it already does for years now as seen in various trials.
    (Participants want to stay on the drug even after completion of the study).

    https://www.santhera.com/assets/files/content/2022-03-30_SannCorpDeck_final.pdf

    Also check the latest news, e.g. https://www.santhera.com/assets/files/press-releases/2022-01-04_SperogenixLicense_e_final_220104_064153.pdf

    I highly recommend taking a closer look into this company. All information is also available in English on the homepage. 

    Bottom line
    80% Success chance, 10 bagger, ethical, love it
    Bullish
  • L
    Lars
    Santhera Pharmaceuticals Holding is an example of a story stock. This company has no fundamental value and is bleeding money. I would not trust a management team that has under delivered year after year. I highly suggest anyone invested in this company consider pulling out or only investing 5 percent of your net worth. The financials have been getting worse and I don’t see a path to profitability. Investing in this company is risky.
    Bearish
  • R
    Ron
    Any news on what's happening with this company?
  • J
    Jordan
    What is this security? Santhera is traded on the Swiss exchange as SWX: SANN.

    So what exactly is this stock? Is it pinned somehow to the Swiss SANN?
  • j
    jiroen
    Very promising pivotal results with Vamorolone in a rare disease indication (DMD), peak sales estimated over USD 550M. Should become standard of care (non-inferiority in efficacy, much better safety profile). Likelihood to be approved very high. Potential for further indications in other diseases.
    Bullish
  • C
    Christian
    With the Vamorolone data next week Santhera should start a strong move up.
    Share price control/manipulation will be over by then.
    GLTAL
  • R
    Rui
    reveragen just confirmed that fda only asks for the existing 24 week data. There is no block to submit vamorolone right away. UK health autority just asked for imediate extended access for vamorolone (next week data will be submited). Trial for Becker dystrophy is fully funded and ready to begin on FDA funding. Age 0 to 18 DMD trial is also about to begin (authorized and fully funded)
  • d
    daniel
    Such a great price after phase 2 pivotal results, but looking at history, this can be dead money for a while. If somebody has any insight… thanks in advance.
  • A
    Antoni
    The price movement was a bit odd today. 20% up and then back to 1.3 per share. What’s going on? People decided to sell at such a low price and on relatively good news.
  • d
    daniel
    Anyone have any idea of when they will publish the Phase 2b results?
  • G
    Gunnar Meister
    Any comments on SP short term? What do you guys see at market cap? I think 250M short term is realistic no? that would be about 18CHF. Thanks and Great day for patients and investors!!!
  • A
    Antoni
    Hi guys, I bought into the company 2 months ago. The pipeline looks impressive. I was wondering what are some of your expectations regarding the stock: i.e whether you think there will be a long term price raises or are you looking more into the prospect of the price going up very high on some announcment like a couple years ago when it hit over 100? Also, any thoughts on why is the stock declining? Seema to have very strong financials
    Bullish
  • J
    John
    SHORTS WILL GET CRUSHED HERE… keep throwing your money away. 80% of the required funding will be secured in CASH!
  • R
    Reto
    sooo, what‘s going on here? they need money! next week!!! and we had a huge volume of 130k shares in the very last minutes on Friday…
  • d
    daniel
    By the way, who is selling this prior to imminent results? Is there a vicious shorter?
  • A
    Antoni
    Wow „ Santhera to receive a double-digit upfront cash payment plus short-term US-regulatory milestones amounting to USD 20 million combined, in a deal valued at USD 124 million” So they will recive around their market cap in upfront cash payment. That’s very positive and significant news. Good start for 2022.
  • R
    Reto
    SANN is no longer in the Top 10 of the most short-selling stocks in Switzerland. It seems that it was hedged for the convertible bond. this stock is still way undervalued!
  • S
    Schtingi
    I reentered, think this could go back to CHF 10. Breakout of longterm downtrend and takeover potential!
Advertisement
Advertisement